School of Medicine, University of Adelaide, Adelaide, SA, Australia.
Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA, Australia; Heart Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
Heart Lung Circ. 2022 May;31(5):616-622. doi: 10.1016/j.hlc.2021.12.015. Epub 2022 Feb 10.
The growth in methamphetamine usage worldwide continues to present increasing societal and health care challenges. With the escalation of its usage in a variety of social demographics, the entity of methamphetamine-associated cardiomyopathy (MA-CMP) has emerged. This entity is increasingly responsible for an important proportion of heart failure burden in both admissions to hospital and in those individuals requiring chronic heart failure care. MA-CMP poses some unique challenges including its recognition, particularly in younger patients presenting with new-onset heart failure, its severity at presentation and complications as well as management options. The challenging nature of methamphetamine addiction and the necessity to achieve abstinence is a fundamental aspect of management of this condition. As methamphetamine use continues at high levels in Australia, the burden of MA-CMP will inevitably increase and, therefore, all clinicians responsible for heart failure management require an awareness of this disease entity and the specific clinical challenges of its care.
全球范围内，甲基苯丙胺（冰毒）的使用量不断增加，这给社会和医疗保健带来了越来越多的挑战。随着其在各种社会人群中的使用不断升级，甲基苯丙胺相关性心肌病（MA-CMP）的问题也日益突出。这种病症在因心力衰竭住院和需要慢性心力衰竭治疗的人群中，占据了相当大的比例，是导致心力衰竭的重要原因之一。MA-CMP 带来了一些独特的挑战，包括其识别，特别是在年轻患者中出现的新发心力衰竭；其临床表现的严重程度、并发症以及治疗选择。冰毒成瘾的治疗难点和戒除毒瘾的必要性，是这种病症管理的一个基本方面。随着澳大利亚甲基苯丙胺的使用量居高不下，MA-CMP 的负担必然会增加，因此，所有负责心力衰竭管理的临床医生都需要了解这种疾病实体以及其治疗的具体临床挑战。
